Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ODS, NCI research grants

This article was originally published in The Tan Sheet

Executive Summary

Applications for R01, R21 grants to conduct "innovative preclinical and clinical research to determine how diet and dietary factors impact DNA methylation and other epigenetic processes involved with cancer prevention" requested by ODS, National Cancer Institute in recent RFA. Collaboration between nutrition and epigenetic/ DNA methylation experts "to study bioactive food components with cancer preventative properties" is encouraged. NCI will fund seven to 10 grants in FY 2004 with a total of $2.5 mil; ODS will offer $800,000 for three or four grants that year. Letters of intent are due by Feb. 18, applications one month later. Under a separate but related RFA, researchers "can extend the goals of active grants to include studies related to the impact of diet and nutrition on epigenetic events"...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel